Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tegoprubart
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Eledon Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Details : AT-1501 (tegoprubart) is an investigational, humanized IgG1 anti-CD40L antibody with high affinity for the CD40 ligand. CD40L plays a pivotal role in immune system activation by mediating both antibody and cellular immune responses.
Brand Name : AT-1501
Molecule Type : Large molecule
Upfront Cash : Undisclosed
January 09, 2023
Lead Product(s) : Tegoprubart
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Eledon Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : HuCo Islet Cells
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : University of Miami
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration will encompass the evaluation of gene-edited pancreatic HuCo™ islet cells in a clinically relevant diabetes model as a prerequisite to advancing to human clinical trials.
Brand Name : HuCo Islet Cells
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
March 09, 2022
Lead Product(s) : HuCo Islet Cells
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : University of Miami
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?